Underlying genetic structure impacts the association between CYP2B6 polymorphisms and response to efavirenz and nevirapine

Determinants of Sustained Viral Suppression in HIV-Infected Patients with Self-Reported Poor Adherence to Antiretroviral Therapy

(2012) Tracy R. Glass et al.   PLoS One

Associations Between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 Alleles in Relation to Efavirenz and Nevirapine Pharmacokinetics in HIV-Infected Individuals

(2012) Sandra G. Heil et al.   THERAPEUTIC DRUG MONITORING

Pharmacogenetics of Toxicity, Plasma Trough Concentration and Treatment Outcome with Nevirapine-Containing Regimen in Anti-Retroviral-Naïve HIV-Infected Adults: An Exploratory Study of the TRIANON ANRS 081 Trial

(2011) Claire Gozalo et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients

(2011) A. Habtewold et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Hypersensitivity reactions to HIV therapy

(2010) Mas Chaponda et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Effect ofCYP2B6,ABCB1, andCYP3A5Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study

(2010) Heather J. Ribaudo et al.   JOURNAL OF INFECTIOUS DISEASES

New approaches to population stratification in genome-wide association studies

(2010) Alkes L. Price et al.   NATURE REVIEWS GENETICS

Measurement of admixture proportions and description of admixture structure in different U.S. populations

(2009) Indrani Halder et al.   HUMAN MUTATION

Associations betweenCYP2B6Polymorphisms and Pharmacokinetics after a Single Dose of Nevirapine or Efavirenz in African Americans

(2009) David W. Haas et al.   JOURNAL OF INFECTIOUS DISEASES

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation

(2008) Ulrich M. Zanger et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

CYP2B6: New Insights into a Historically Overlooked Cytochrome P450 Isozyme

(2008) Hongbing Wang et al.   CURRENT DRUG METABOLISM

Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients

(2008) C. Wyen et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Aberrant Splicing Caused by Single Nucleotide Polymorphism c.516G>T [Q172H], a Marker of CYP2B6*6, Is Responsible for Decreased Expression and Activity of CYP2B6 in Liver

(2008) M. H. Hofmann et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS